Latest News for: pnkp
Edit
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization (Onco-Innovations Ltd)
Public Technologies 16 Jun 2026
("Kuano"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches ... PNKP target.
Edit
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP ...
ACCESSWIRE 10 Jun 2026
Edit
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate (Onco-Innovations Ltd)
Public Technologies 16 May 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 131814623) .
Edit
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
ACCESSWIRE 16 May 2026
These activities are an important step in preparing our PNKP inhibitor technology for the requirements of future clinical-stage development," said Thomas O'Shaughnessy, Chief Executive Officer of Onco-Innovations.
Edit
Norfolk Daily News
09 May 2026
Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Edit
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies (Onco-Innovations Ltd)
Public Technologies 02 May 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 131432033) .
Edit
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Pharmiweb 02 May 2026
This delivery system is proven1 to enhance tumor-targeted delivery of PNKP inhibition in animal models, with the goal of improving therapeutic efficacy while reducing systemic toxicity.
Edit
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram ...
ACCESSWIRE 02 May 2026
This delivery system is proven1 to enhance tumor-targeted delivery of PNKP inhibition in animal models, with the goal of improving therapeutic efficacy while reducing systemic toxicity.
Edit
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program (Onco-Innovations Ltd)
Public Technologies 29 Apr 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 131303212) .
Edit
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical ...
ACCESSWIRE 29 Apr 2026- 1